TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
NZ537752A
(en)
|
2002-07-29 |
2006-12-22 |
Rigel Pharmaceuticals Inc |
Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
|
ES2421139T3
(es)
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
AU2005322855B2
(en)
|
2004-12-30 |
2012-09-20 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
ES2337496T3
(es)
|
2005-01-19 |
2010-04-26 |
Rigel Pharmaceuticals, Inc. |
Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos.
|
KR101302945B1
(ko)
|
2005-02-04 |
2013-09-06 |
아스트라제네카 아베 |
키나제 억제제로서 유용한 피라졸릴아미노피리딘 유도체
|
US7297700B2
(en)
|
2005-03-24 |
2007-11-20 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
JP5225079B2
(ja)
|
2005-06-08 |
2013-07-03 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jak経路の阻害のための組成物および方法
|
WO2007023382A2
(en)
*
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
US8604042B2
(en)
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
AU2006309013B2
(en)
*
|
2005-11-01 |
2012-06-28 |
Impact Biomedicines, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8133900B2
(en)
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
WO2007120980A2
(en)
|
2006-02-17 |
2007-10-25 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
US20070293494A1
(en)
*
|
2006-06-15 |
2007-12-20 |
Djung Jane F |
2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
|
EP2032543A1
(de)
|
2006-06-15 |
2009-03-11 |
Boehringer Ingelheim International GmbH |
2-anilin-4-aminoalkylenaminopyrimidine
|
UY30444A1
(es)
*
|
2006-06-30 |
2008-01-31 |
Astrazeneca Ab |
Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
|
EP2043651A2
(de)
|
2006-07-05 |
2009-04-08 |
Exelixis, Inc. |
Verfahren zur verwendung von igf1r und abl-kinase-modulatoren
|
CA2673125C
(en)
|
2006-10-19 |
2015-04-21 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2008051547A1
(en)
|
2006-10-23 |
2008-05-02 |
Cephalon, Inc. |
Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
|
US7803940B2
(en)
|
2006-11-24 |
2010-09-28 |
Takeda Pharmaceutical Company Limited |
Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
|
TW200838559A
(en)
*
|
2006-11-29 |
2008-10-01 |
Imclone Systems Inc |
Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
|
NZ577197A
(en)
*
|
2006-12-08 |
2011-02-25 |
Irm Llc |
Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
|
DK2091918T3
(en)
*
|
2006-12-08 |
2014-12-01 |
Irm Llc |
Compounds and Compositions as Protein Kinase Inhibitors
|
PL2101759T3
(pl)
|
2006-12-14 |
2019-05-31 |
Exelixis Inc |
Sposoby stosowania inhibitorów MEK
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US20100204231A1
(en)
*
|
2007-05-04 |
2010-08-12 |
Astrazeneca Ab |
Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer
|
UA99459C2
(en)
*
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
US20090029992A1
(en)
*
|
2007-06-11 |
2009-01-29 |
Agoston Gregory E |
Substituted pyrazole compounds
|
AR067354A1
(es)
|
2007-06-29 |
2009-10-07 |
Sunesis Pharmaceuticals Inc |
Compuestos utiles como inhibidores de la raf quinasa
|
CN101743242A
(zh)
|
2007-06-29 |
2010-06-16 |
苏尼西斯制药有限公司 |
用作raf激酶抑制剂的杂环化合物
|
JP5489997B2
(ja)
|
2007-07-19 |
2014-05-14 |
シマベイ セラピューティクス, インコーポレーテッド |
糖尿病および代謝疾患の治療のためのRUP3またはGPRl19受容体のアゴニストとしてのN−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
|
WO2009027736A2
(en)
*
|
2007-08-27 |
2009-03-05 |
Astrazeneca Ab |
2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
|
EP2190826A2
(de)
*
|
2007-08-28 |
2010-06-02 |
Irm Llc |
2-biphenylamino-4-aminopyrimidinderivate als kinaseinhibitoren
|
WO2009056886A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Astrazeneca Ab |
Pyrimidine derivatives and their use as modulators of fgfr activity
|
EP3210609A1
(de)
|
2008-05-21 |
2017-08-30 |
Ariad Pharmaceuticals, Inc. |
Phosphorhaltige derivate als kinasehemmer
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
US8569298B2
(en)
|
2008-06-17 |
2013-10-29 |
Astrazeneca Ab |
Pyridine compounds
|
WO2009158431A2
(en)
*
|
2008-06-25 |
2009-12-30 |
Irm Llc |
Compounds and compositions as kinase inhibitors
|
PE20100087A1
(es)
*
|
2008-06-25 |
2010-02-08 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
US8445505B2
(en)
*
|
2008-06-25 |
2013-05-21 |
Irm Llc |
Pyrimidine derivatives as kinase inhibitors
|
CA2986640C
(en)
*
|
2008-06-27 |
2019-03-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
CN104230901A
(zh)
|
2008-09-15 |
2014-12-24 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
EP2389372B1
(de)
|
2009-01-23 |
2015-09-09 |
Rigel Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur inhibierung des jak-pfades
|
SG173647A1
(en)
|
2009-02-13 |
2011-10-28 |
Shionogi & Co |
Novel triazine derivative and pharmaceutical composition containing same
|
CA2760794C
(en)
|
2009-05-05 |
2017-07-25 |
Dana Farber Cancer Institute |
Egfr inhibitors and methods of treating disorders
|
CN102459236B
(zh)
*
|
2009-05-27 |
2014-10-29 |
Abbvie公司 |
激酶活性的嘧啶抑制剂
|
CA2763624A1
(en)
|
2009-05-27 |
2010-12-02 |
Abbott Laboratories |
Pyrimidine inhibitors of kinase activity
|
CA2763631A1
(en)
*
|
2009-05-27 |
2010-12-02 |
Abbott Laboratories |
Pyrimidine inhibitors of kinase activity
|
JP2012529522A
(ja)
*
|
2009-06-10 |
2012-11-22 |
アボット・ラボラトリーズ |
キナーゼ阻害剤としての2−(1h−ピラゾール−4−イルアミノ)−ピリミジン
|
EP2464633A1
(de)
|
2009-08-14 |
2012-06-20 |
Boehringer Ingelheim International GmbH |
Regioselektive herstellung von 2-amino-5-trifluormethylpyrimidinderivaten
|
US8933227B2
(en)
|
2009-08-14 |
2015-01-13 |
Boehringer Ingelheim International Gmbh |
Selective synthesis of functionalized pyrimidines
|
US20110053916A1
(en)
|
2009-08-14 |
2011-03-03 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine compounds as tuberculosis inhibitors
|
ES2497566T3
(es)
|
2009-10-01 |
2014-09-23 |
Cymabay Therapeutics, Inc. |
Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
|
CA2784807C
(en)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
WO2011083391A2
(en)
|
2010-01-05 |
2011-07-14 |
Pfizer Inc. |
Biomarkers for anti-igf-ir cancer therapy
|
MX2012013274A
(es)
|
2010-05-21 |
2013-05-28 |
Chemilia Ab |
Novedosos derivados de la pirimidina.
|
JP5713367B2
(ja)
|
2010-06-04 |
2015-05-07 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Lrrk2モジュレーターとしてのアミノピリミジン誘導体
|
CN103037843A
(zh)
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
|
JP5594706B2
(ja)
|
2010-08-10 |
2014-09-24 |
塩野義製薬株式会社 |
トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
|
KR20130099040A
(ko)
|
2010-08-10 |
2013-09-05 |
셀진 아빌로믹스 리서치, 인코포레이티드 |
Btk 억제제의 베실레이트 염
|
US9212130B2
(en)
|
2010-08-10 |
2015-12-15 |
Shionogi & Co., Ltd. |
Heterocyclic derivative and pharmaceutical composition comprising the same
|
EP2635285B1
(de)
|
2010-11-01 |
2017-05-03 |
Celgene Avilomics Research, Inc. |
Heteroarylverbindungen und ihre verwendung
|
US8975249B2
(en)
|
2010-11-01 |
2015-03-10 |
Celgene Avilomics Research, Inc. |
Heterocyclic compounds and uses thereof
|
WO2012060847A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
BR112013011600B1
(pt)
*
|
2010-11-10 |
2022-01-11 |
Genentech, Inc |
Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
|
US8796255B2
(en)
|
2010-11-10 |
2014-08-05 |
Celgene Avilomics Research, Inc |
Mutant-selective EGFR inhibitors and uses thereof
|
UY33817A
(es)
*
|
2010-12-21 |
2012-07-31 |
Boehringer Ingelheim Int |
?nuevas oxindolpirimidinas bencílicas?.
|
WO2012106556A2
(en)
|
2011-02-02 |
2012-08-09 |
Amgen Inc. |
Methods and compositons relating to inhibition of igf-1r
|
US9006241B2
(en)
|
2011-03-24 |
2015-04-14 |
Noviga Research Ab |
Pyrimidine derivatives
|
BR112013027734A2
(pt)
|
2011-05-04 |
2017-08-08 |
Ariad Pharma Inc |
compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica
|
BR112014003997A2
(pt)
|
2011-08-25 |
2017-03-21 |
Hoffmann La Roche |
composto, método para inibição da atividade de pak1 em uma célula e paciente, método para o tratamento ou melhoria da gravidade do câncer ou de um distúrbio hiperproliferativo em um paciente, utilização do composto e composição
|
CA2853498A1
(en)
|
2011-10-28 |
2013-05-02 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
AU2012335541B2
(en)
|
2011-11-11 |
2017-07-06 |
Duke University |
Combination drug therapy for the treatment of solid tumors
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
JP2015504876A
(ja)
|
2011-12-22 |
2015-02-16 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
セリン/トレオニンキナーゼ阻害剤としての2,4−ジアミン−ピリミジン誘導体
|
WO2013118855A1
(ja)
|
2012-02-09 |
2013-08-15 |
塩野義製薬株式会社 |
複素環および炭素環誘導体
|
GB201204384D0
(en)
*
|
2012-03-13 |
2012-04-25 |
Univ Dundee |
Anti-flammatory agents
|
EP2825041B1
(de)
|
2012-03-15 |
2021-04-21 |
Celgene CAR LLC |
Feste formen eines epidermalen wachstumsfaktor-rezeptor-kinase-hemmers
|
RS57901B1
(sr)
|
2012-03-15 |
2019-01-31 |
Celgene Car Llc |
Soli inhibitora kinaze receptora epidermalnog faktora rasta
|
BR112014026952B1
(pt)
*
|
2012-05-03 |
2022-03-15 |
Genentech, Inc |
Derivados de aminopirimidina pirazol e composição que os compreende
|
JP6469567B2
(ja)
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Egfr発動性がんの細胞増殖阻害用化合物
|
US8980259B2
(en)
|
2012-07-20 |
2015-03-17 |
Novartis Ag |
Combination therapy
|
EP2909194A1
(de)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Hemmer der cyclinabhängigen kinase 7 (cdk7)
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
BR112015010109A2
(pt)
*
|
2012-11-05 |
2017-07-11 |
Nant Holdings Ip Llc |
derivados de indol-5-ol substituídos e suas aplicações terapêuticas
|
EP2935226A4
(de)
|
2012-12-21 |
2016-11-02 |
Celgene Avilomics Res Inc |
Heteroarylverbindungen und verwendungen davon
|
CN103202843B
(zh)
*
|
2012-12-31 |
2015-04-29 |
刘强 |
一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
|
PE20151274A1
(es)
|
2013-02-08 |
2015-09-12 |
Celgene Avilomics Res Inc |
Inhibidores de erk y sus usos
|
US9550760B2
(en)
|
2013-03-15 |
2017-01-24 |
Nantbioscience, Inc. |
Substituted indol-5-ol derivatives and their therapeutic applications
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
TWI637949B
(zh)
|
2013-06-14 |
2018-10-11 |
塩野義製藥股份有限公司 |
胺基三衍生物及含有其等之醫藥組合物
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
CN104926795B
(zh)
*
|
2014-03-17 |
2017-11-10 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
MX2016012574A
(es)
|
2014-03-28 |
2017-09-26 |
Calitor Sciences Llc |
Compuestos heteroarilo sustituidos y metodos de uso.
|
US10300058B2
(en)
|
2014-04-18 |
2019-05-28 |
Xuanzhu Pharma Co., Ltd. |
Tyrosine kinase inhibitor and uses thereof
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2016014551A1
(en)
|
2014-07-21 |
2016-01-28 |
Dana-Farber Cancer Institute, Inc. |
Macrocyclic kinase inhibitors and uses thereof
|
WO2016014542A1
(en)
|
2014-07-21 |
2016-01-28 |
Dana-Farber Cancer Institute, Inc. |
Imidazolyl kinase inhibitors and uses thereof
|
AU2015299142B2
(en)
|
2014-08-04 |
2020-05-07 |
Nuevolution A/S |
Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
|
CA2955082A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Uses of salt-inducible kinase (sik) inhibitors
|
ES2741785T3
(es)
|
2014-08-13 |
2020-02-12 |
Celgene Car Llc |
Formas y composiciones de un inhibidor de ERK
|
CN105461694B
(zh)
*
|
2014-09-27 |
2019-05-24 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
WO2016060963A1
(en)
*
|
2014-10-14 |
2016-04-21 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
US10870651B2
(en)
|
2014-12-23 |
2020-12-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CN104817553B
(zh)
*
|
2015-03-13 |
2018-11-09 |
华东师范大学 |
一种芳香基-杂环取代的嘧啶二胺类化合物及其衍生物及其医药用途
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
EP3307728A4
(de)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
Kombinationstherapie von transkriptionshemmern und kinasehemmern
|
WO2017044858A2
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
EP3347097B1
(de)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
WO2017156527A1
(en)
*
|
2016-03-11 |
2017-09-14 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
|
DK3433253T3
(da)
|
2016-04-28 |
2020-04-06 |
Theravance Biopharma R&D Ip Llc |
Pyrimidinforbindelse som JAK-kinase-inhibitorer
|
AU2017275657B2
(en)
|
2016-06-02 |
2021-08-19 |
Novartis Ag |
Potassium channel modulators
|
IL299412A
(en)
|
2016-06-16 |
2023-02-01 |
Denali Therapeutics Inc |
Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
|
US10954242B2
(en)
|
2016-07-05 |
2021-03-23 |
The Broad Institute, Inc. |
Bicyclic urea kinase inhibitors and uses thereof
|
CA3032432A1
(en)
|
2016-08-03 |
2018-02-08 |
Charles A. Mcwherter |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
US11241435B2
(en)
|
2016-09-16 |
2022-02-08 |
The General Hospital Corporation |
Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
|
JOP20190080A1
(ar)
|
2016-10-14 |
2019-04-11 |
Bayer Pharma AG |
مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
|
UA123810C2
(uk)
|
2017-01-23 |
2021-06-02 |
Цадент Терапеутікс, Інк. |
Модулятори калієвих каналів
|
EP3589284A4
(de)
|
2017-02-28 |
2020-12-16 |
The General Hospital Corporation |
Verwendung von pyrimidindopyrimidinonen als sik-inhibitoren
|
WO2019046163A1
(en)
*
|
2017-08-28 |
2019-03-07 |
Zhihong Chen |
SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND ASSOCIATED THERAPEUTIC METHODS
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
TWI740288B
(zh)
*
|
2018-11-27 |
2021-09-21 |
大陸商江蘇豪森藥業集團有限公司 |
含氮雜芳類衍生物調節劑、其製備方法和應用
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
KR20220064369A
(ko)
|
2019-08-14 |
2022-05-18 |
인사이트 코포레이션 |
Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
|
CR20220170A
(es)
|
2019-10-11 |
2022-10-10 |
Incyte Corp |
Aminas bicíclicas como inhibidoras de la cdk2
|
US11447479B2
(en)
|
2019-12-20 |
2022-09-20 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
US11613532B2
(en)
|
2020-03-31 |
2023-03-28 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
EP4126874A1
(de)
|
2020-03-31 |
2023-02-08 |
Nuevolution A/S |
Gegen nukleare rezeptoren aktive verbindungen
|
IL300906A
(en)
*
|
2020-08-26 |
2023-04-01 |
Nalo Therapeutics |
Modulators of MYC family proto-oncogene proteins
|
CN112225729B
(zh)
*
|
2020-11-04 |
2022-02-01 |
四川大学华西医院 |
嘧啶类衍生物、其制备方法和应用以及药物组合物
|
CN113185428B
(zh)
*
|
2021-05-10 |
2022-07-15 |
安徽省庆云医药股份有限公司 |
一种4-甲基-3-氧代戊腈的合成方法
|
WO2023159307A1
(en)
*
|
2022-02-23 |
2023-08-31 |
Repare Therapeutics Inc. |
Polo-like kinase 4 (plk4) inhibitors, pharmaceutical compositions, methods of preparation and uses thereof
|
WO2023164612A1
(en)
*
|
2022-02-25 |
2023-08-31 |
Nalo Therapeutics |
Modulators of myc family proto-oncogene protein
|